Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol to FDA for Major Depressive Disorder (MDD) Sep 7, 2010
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compound RX-8243 Sep 2, 2010
Rexahn Pharmaceuticals Announces Formation of Scientific Advisory Board in Major Depressive Disorder Jul 6, 2010
Rexahn Pharmaceuticals Retains Investment Banker Frederick Frank to Provide Advisory Services Jun 8, 2010
Rexahn Pharmaceuticals to Initiate Zoraxel Phase IIb Trial for Treatment of Erectile Dysfunction May 13, 2010
Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-8243 at the American Association for Cancer Research Apr 15, 2010
Rexahn Pharmaceuticals Issues Additional Comments and Clarifications on its Phase IIa Study Results of Serdaxin in Major Depressive Disorder (MDD) Apr 14, 2010
Rexahn Pharmaceuticals Announces Phase IIa Study Results of Serdaxin in Major Depressive Disorder (MDD) Apr 13, 2010